ABVC BioPharma Reports $5.1M Net Loss Through Q3 FY2025, Raises $3.6M in Financing

ABVC BioPharma Widens Nine-Month Loss to $5.14 Million

ABVC BioPharma, Inc., a clinical-stage biopharmaceutical firm, reported a net loss of $5.14 million for the nine months ending September 30, 2025, compared to a $4.17 million loss for the same period in 2024. The company generated $35,950 in revenue during the nine-month period, down sharply from $507,623 a year earlier. Read more earnings reports.

Operating expenses climbed to $4.95 million from $4.51 million year-over-year. The operating loss for the period stood at $4.95 million versus $4.00 million in the prior-year period.

Third-Quarter Results

For the three months ending September 30, 2025, ABVC BioPharma reported no revenue, a reversal from the $389,276 posted in the same quarter of 2024. The company recorded a net loss of $2.04 million for the third quarter, compared to a $394,769 loss in Q3 2024.

Operating expenses for the quarter reached $1.96 million, nearly triple the $691,296 reported in the prior-year quarter. Selling, general, and administrative expenses accounted for $798,253 of that total, up from $557,596 a year earlier. Research and development spending declined to $29,890 from $37,825.

Balance Sheet and Cash Position

Total assets surged to $21.21 million as of September 30, 2025, from $7.54 million at year-end 2024. The increase was driven largely by property, plant, and equipment, which jumped to $12.85 million from $511,088. Cash and cash equivalents stood at $192,068, down from $248,382 at the end of December 2024.

Stockholders' equity rose to $12.06 million from $1.23 million, reflecting capital raises during the period. The company issued 10.32 million common shares during the nine months, bringing total shares outstanding to 24.19 million as of September 30, 2025.

Cash Flow Summary

ABVC BioPharma consumed $2.40 million in operating activities during the nine months, compared to $1.11 million in the prior-year period. Investing activities used $1.18 million, while financing activities brought in $3.56 million, primarily from equity issuances. The company reported $3.49 million in gross proceeds from stock sales.

Current liabilities totaled $6.54 million as of September 30, 2025, roughly flat compared to $6.56 million at year-end 2024. Total liabilities stood at $6.72 million, down slightly from $6.82 million.